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Extra virgin olive oil (EVOO) polyphenols, including the secoiridoids oleocanthal (OLC) and 24 
oleacein (OLE), are attracting attention because of their beneficial effects on health. Data on 25 
OLC and OLE bioavailability are scarce, as most research on EVOO polyphenols has 26 
concentrated on hydroxytyrosol, tyrosol, and oleuropein. Consequently, relevant goals for 27 
future research are the elucidation of OLC and OLE bioavailability and finding evidence for 28 
their beneficial effects through pre-clinical and clinical studies. The aim of this review is to 29 
shed light on OLC and OLE, focusing on their precursors in the olive fruit and the impact of 30 
agronomic and processing factors on their presence in EVOO. Also discussed are their 31 
bioavailability and absorption, and finally, their bioactivity and health-promoting properties.  32 
 33 
 34 
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1. Introduction 38 
Extra virgin olive oil (EVOO) is a staple of the Mediterranean diet and is highly appreciated 39 
for its unique nutritional and organoleptic attributes (Polari et al. 2018). A Mediterranean diet 40 
rich in EVOO may prevent type 2 diabetes, cancer, neurodegenerative and cardiovascular  41 
diseases (Anna Tresserra-Rimbau et al. 2011; A. Tresserra-Rimbau et al. 2014; Martínez-42 
González et al. 2015). The nutritional and health-promoting properties of EVOO are mainly 43 
attributed to a high content of monounsaturated acids (C18:1, between 55-83%), its minor 44 
components (alcohols, sterols and hydrocarbons), and phenolic compounds (Leporini et al. 45 
2018), particularly phenolic alcohols and secoiridoid derivatives (Soler et al. 2010). The 46 
phenolic composition of EVOO depends on a very complex multivariate interaction between 47 
the genotype and agronomic, environmental and technological factors (Chiacchierini et al. 48 
2007), the processing steps critically affecting yield, quality and nutritional attributes 49 
(Fregapane and Salvador 2013).  50 
During the mechanical extraction process, mainly the crushing and malaxing steps, 51 
hydrolysis reactions take place catalyzed by the endogenous β-glucosidase and 52 
oxidoreductase enzymes of the olive fruits acting on phenolic glycosides. Subsequently, the 53 
aglycone derivatives known as secoiridoids (SEC) are released (López de las Hazas et al. 54 
2016; Servili et al. 2004; Velázquez-Palmero et al. 2017; Clodoveo et al. 2014; Alessandra 55 
Bendini, Lorenzo Cerretani, Alegria Carrasco-Pancorbo, Ana Maria Gómez-Caravaca, 56 
Antonio Segura-Carretero 2007; Hachicha Hbaieb et al. 2015). 57 
Among the different types of SEC, two compounds have recently attracted attention: 58 
oleocanthal (OLC) and oleacein (OLE). These SEC were identified for the first time in olive 59 
oil by Montedoro and co-workers in 1993 (Montedoro et al. 1993), but it was not until 2005 60 
that Beauchamp and co-workers discovered the anti-inflammatory activity of OLC 61 
(Beauchamp et al. 2005). Since then, other biological properties have been attributed to this 62 
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compound, including anti-cancer (LeGendre, Breslin, and Foster 2015) and anti-Alzheimer 63 
effects, both in vitro and in vivo (Qosa et al. 2015; Monti et al. 2012), and a protective role 64 
against arthropathy in vitro (Morena Scotece et al. 2012) and against cardiovascular diseases 65 
in vivo and in human trials (Agrawal et al. 2017). OLE, like OLC, decreases cyclooxygenase 66 
(COX) 2 activity, thereby reducing inflammation (Rosignoli et al. 2013), and is also thought 67 
to be the main component responsible for the anti-sclerotic effect of EVOO (Naruszewicz, 68 
Czerwiska, and Kiss 2015). OLE has also shown in vitro activity against cancer (Roberto 69 
Fabiani et al. 2006) and an anti-estrogenic effect (Keiler et al. 2015). 70 
Although SEC are the most abundant and complex family of phenolic compounds in 71 
EVOO, their bioavailability has been little studied (Silva et al. 2017b), either in in vitro or in 72 
preclinical and clinical studies. The processes of OLC and OLE absorption and metabolism 73 
are important for understanding their biological properties in vivo (Corona et al. 2006; 74 
Deiana, Serra, and Corona 2018). New research is required to investigate if intestinal 75 
absorption and/or metabolism are the main factors that determine OLC and OLE 76 
bioavailability and mechanisms of action (Pinto et al. 2011). 77 
 The aim of this work is to review all the known factors involved in the beneficial 78 
effects of OLC and OLE, ranging from their precursors in the olive fruit and their production 79 
in EVOO to their absorption and bioavailability, and finally, their bioactivity and health-80 
promoting properties. 81 
 82 
2. Biosynthesis and biotransformation of secoiridoids in olive oil 83 
2.1 Biosynthesis of secoiridoids in Olea europaea L. 84 
Olea europaea L. has an economic importance in the Mediterranean area and provides 85 
different commercial products, including food, lumber, cosmetics, and above all, olive oil 86 
(Obied et al. 2008). The beneficial effects of a Mediterranean diet on cardiovascular diseases 87 
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have been partially attributed to a high EVOO consumption (Ramon Estruch, M.D., Ph.D., 88 
Emilio Ros, M.D., Ph.D.Jordi Salas-Salvado, M.D. et al. 2013), and the identification of anti-89 
inflammatory properties of OLC (Beauchamp et al. 2005) has made SEC a hot research topic. 90 
New oleoside conjugates and metabolites in Olea europaea L. have been identified, and the 91 
behavior of these compounds during processing and storage of olive products has been 92 
described, but to date scarce attention has been directed at OLC and OLC. 93 
The diverse range of SEC in the Oleaceae family is of chemotaxonomic interest 94 
(Obied et al. 2008). In their review of iridoid biosynthesis in the Oleaceae family, Jensen, 95 
Franzyk, and Wallander (2002) described that SEC are derived from iridoids by cleavage of 96 
the cyclopentane ring and from the formation of deoxyloganic acid via iridodial and iridotrial 97 
(Jensen, Franzyk, and Wallander 2002). They reported at least five different routes, 98 
deoxyloganic acid being the common intermediate. Many SEC are produced in route 1 via 99 
loganin and secologanin (Jensen, Franzyk, and Wallander 2002) (Fig. 1). The most interesting 100 
SEC in Olea europaea L., due to their bioactive properties, are oleosides or oleosidic 101 
secoiridoids, which are characterized by an exocyclic 8,9-olefinic functionality.  102 
The major oleosides in Olea europaea L. are oleuropein and ligstroside, characterized 103 
as esters of elenolic acid linked to hydroxytyrosol (OH-TY) or tyrosol (TY), respectively. 104 
SEC conjugates bearing an esterified phenolic moiety, such as oleuropein, are produced by a 105 
branching in the mevalonic acid pathway, where it merges with an oleoside moiety from the 106 
phenylpropanoid metabolism. The biosynthesis of oleuropein, the most extensively studied 107 
oleoside, is affected by the olive fruit ripening process, and whether the season is low or high 108 
fruiting (Obied et al. 2008). 109 
2.2 Agronomic and processing factors in the biosynthesis and biotransformation of SEC 110 
Olive oil is obtained from the fruit of olive trees (Olea europaea, L.) using mechanical 111 
techniques (Leone et al. 2015) with three main steps: preparation of the paste (crushing and 112 
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malaxation), and solid-liquid and liquid-liquid separations. The composition and 113 
concentration of polyphenols in EVOO and virgin olive oil (VOO) are strongly affected by 114 
agronomic, biochemical and technological factors (Clodoveo et al. 2014). 115 
The olive fruit composition, mainly phenolic compounds content, can be strongly 116 
affected by agronomic factors as genetics, cultivar, ripening stage and environmental growth 117 
conditions including biotic and abiotic stresses (Peres, Martins, and Ferreira-Dias 2017; S. 118 
Cicerale 2012). The content of phenolic glycosides, initially present in the olive tissues, and 119 
the activity of various endogenous enzymes also play a role in the olive fruit composition. 120 
The OLC and OLE concentration has been positively correlated with an early harvest of 121 
olives (Gómez-Rico, Fregapane, and Salvador 2008; Karkoula et al. 2012; de Torres et al. 122 
2016), because in the green stage, the level of β-glucosidase activity increases proportionally 123 
with the oleuropein and ligstroside content, whereas in the black stage, when the phenolic 124 
glycoside concentration declines, the glucosidase activity is low (Clodoveo et al. 2014). 125 
The main biochemical factors affecting the phenolic compound composition are the 126 
endogenous enzymes of the olive fruits, such as β-glycosidase (which hydrolyzes phenolic 127 
glycosides) and oxidoreductases like polyphenoloxidases and peroxidases (which oxidase 128 
phenolic compounds) (Servili et al. 2004; Peres, Martins, and Ferreira-Dias 2017).  129 
The crushing process is the key technological factor in the release of endogenous 130 
enzymes and the commencement of their activities, which depends on the temperature, 131 
particle size of olive fruit fragments, exposure to atmospheric oxygen and the differential 132 
crushing of the olive tissues (Maurizio Servili, Agnese Taticchi, Sonia Esposto 2012; 133 
Clodoveo et al. 2014). The endogenous enzymatic activity can be modulated during 134 
malaxation by controlling its duration and the atmospheric conditions inside the malaxer 135 
(Clodoveo 2012). The concentration of OLC and OLE was enhanced by increasing the 136 
temperature during malaxation of the olive paste up to 30 and 35 °C (Lukić et al. 2018; 137 
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Taticchi et al. 2013; de Torres et al. 2016). The enzymatic oxidation of the SEC aglycones by 138 
polyphenoloxidases and peroxidases (Clodoveo 2012; Taticchi et al. 2013) may be reduced at 139 
higher malaxation temperatures, boosting the release of phenols from the cell wall 140 
polysaccharides and other olive tissues catalyzed by the endogenous hemicellulases and 141 
polygalacturonases (Clodoveo 2012; Taticchi et al. 2013; Esposto et al. 2013; Vierhuis et al. 142 
2001). Moreover, a higher temperature can increase the partition coefficient between oil and 143 
water phases in olive paste (Gómez-Rico, Fregapane, and Salvador 2008), enhancing the 144 
solubility of these compounds in the oil phase (de Torres et al. 2016). 145 
3 Bioavailability, absorption and metabolism of SEC 146 
3.1 Bioavailability 147 
The bioavailability of OLC and OLE has been scarcely studied, either in in vitro 148 
studies or in preclinical and clinical trials. Most research in this field has been focused on the 149 
phenolics OH-TY, TY and oleuropein. Although the biological activities of the phenolic 150 
compounds present in VOO have been clearly demonstrated (Sara Cicerale, Lucas, and Keast 151 
2010), it is difficult to find evidence for the specific role of each component in the beneficial 152 
effects of the oil, or for the synergistic activity of a combination of compounds. To achieve 153 
any effect in a specific tissue or organ, the bioactive compounds must be bioavailable. Thus, 154 
data on the bioavailability of OLC and OLE in humans (and even animals) would be of great 155 
interest to assess their potential health benefits.  156 
Bioavailability is the amount of a substance from an administered matrix that appears 157 
in the systemic circulation. Oral bioavailability depends on the degree of absorption, but also 158 
on the extent of the first-pass metabolism, which can occur either in the intestine or the liver, 159 
before the substance reaches the systemic circulation. It is therefore essential to study how 160 
OLC and OLE are absorbed and biotransformed/excreted, which will be discussed below. 161 
Other factors such as diet, genomic profile, enzymatic activity and colonic microflora can also 162 
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influence the bioavailability of the ingested phenolic compounds.  It is thought that OLE may 163 
be absorbed in the small intestine by passive diffusion through the membrane due to its 164 
favorable partition coefficient (log p = 1.02). In addition, OLE was found to be stable at 165 
gastric acid pH, 67% remaining unchanged after 4 h of incubation (Naruszewicz, Czerwiska, 166 
and Kiss 2015). 167 
3.2 Absorption 168 
Absorption is a complex kinetic process that depends on numerous physiological, 169 
physicochemical, and dosage form factors (Griffin and Driscoll 2007). The absorption and 170 
metabolism of phenolic compounds are determined primarily by their physicochemical 171 
characteristics (Guo et al. 2017), including molecular size (López de las Hazas et al. 2016), 172 
basic structural properties, polarity (Vissers et al. 2002; Sara Cicerale, Lucas, and Keast 173 
2010), degree of polymerization or glycosylation (Carbonell-Capella et al. 2014), solubility, 174 
lipophilicity and conjugation with other phenols (Guo et al. 2017). The chemical structure of 175 
polyphenols, more than the concentration, determines the rate and extent of absorption and 176 
the nature of the metabolites circulating in the plasma (D’Archivio et al. 2007). 177 
The mechanism by which absorption of olive oil phenolic compounds occurs remains 178 
unclear. Once olive oil has been ingested, it produces a micellar solution composed of a lipid 179 
and an aqueous phase (Singh, Ye, and Horne 2009). Polyphenol glycosides can be modified in 180 
the oral cavity by the hydrolytic activity of saliva, although most pass through the stomach to 181 
reach the small intestine and colon. Before absorption in the small intestine, these compounds 182 
must be hydrolyzed by intestinal enzymes (Vissers et al. 2002), and similarly, when they reach 183 
the colon, they are usually metabolized by the microbiota (D’Archivio et al. 2010).  184 
Chemical hydrolysis of SEC can take place in the acidic medium of the stomach 185 
(Lopez et al. 2014; Corona et al. 2006) or in the more alkaline conditions of the small 186 
intestine (Soler et al. 2010; Pinto et al. 2011). This leads to an increase of free phenolic 187 
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alcohols (Muriana et al. 2017) released into the aqueous phase and becoming available for 188 
absorption. SEC remain highly stable during digestion in the mouth, whereas in the gastric, 189 
duodenal and colonic regions they undergo important losses; their recovery index in the 190 
duodenal step was found to oscillate between 7 and 34% (Quintero-Flórez et al. 2017). 191 
Studies indicate that SEC, which are apparently not absorbed in the small intestine, are likely 192 
to reach the large intestine to be degraded by the colonic microflora (Corona et al. 2006). 193 
Some authors suggest that the breakdown of the ester bond of OLC is relatively probable, 194 
either in acidic or alkaline conditions or by esterases located in the small intestine or the liver 195 
(Rubió et al. 2012) (Fig 2). 196 
 The absorption of SEC is not well elucidated, a possible mechanism being passive 197 
diffusion (Scalbert and Williamson 2000). SEC are a group of coumarin-like compounds, 198 
which are usually glycosidically bound (Corona et al. 2006). The absorption of SEC through 199 
passive diffusion would therefore require the removal of the attached glycosyl moiety 200 
(Vissers et al. 2002) by enzymes (glycosidases), which can be present in the gastrointestinal 201 
mucosa or secreted by the colon microflora (Scalbert and Williamson 2000).  202 
Another pathway of polyphenol absorption is the one supported by Hollman et al. 203 
(1999), who described how glucosides can promote polyphenol absorption across the 204 
intestinal epithelium. They suggested this occurs by interaction with the sodium-dependent 205 
glucose transporter SGLT1 or, as mentioned above, by the action of glycosidases (Hollman et 206 
al. 1999).  207 
3.3 Metabolism  208 
 Biotransformation is the chemical alteration of a foreign molecule in the body (Chan 209 
1959) to facilitate its elimination, and is fundamental to the understanding and evaluation of 210 
the health benefits associated with phenolic compounds (S Cicerale, Lucas, and Keast 2012). 211 
The metabolism of SEC can be carried out by phase I (hydrogenation, hydroxylation, 212 
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hydration, etc.) or phase II reactions (glucuronidation, methylation, sulphation, etc.). The 213 
OLC metabolites found in plasma and urine are the result of hydrogenation, hydration (Silva 214 
et al. 2017a; García-Villalba et al. 2010), hydroxylation and glucuronidation (García-Villalba 215 
et al. 2010) and are formed mainly in the small intestine and liver.  216 
Although the liver appears to be the major organ involved in glucuronidation, high 217 
levels of some UGT isoforms are found in the kidney and intestine, suggesting that 218 
extrahepatic glucuronidation may be significant (Fisher et al. 2001; Scalbert and Williamson 219 
2000). 220 
Catechol-O-methyl (COMT) transferase, present in a wide range of tissues, is 221 
responsible for the methyl conjugation process. It catalyzes the transfer of a methyl group 222 
from S-adenosyl-L-methionine to phenolic compounds with an O-diphenolic (catechol) 223 
structure (Manach et al. 2004). Its activity is highest in the liver and kidneys, although 224 
significant methylation has been reported for catechin in the small intestine of rats (Manach et 225 
al. 2004). Methylated forms of OLC have not been detected (Silva et al. 2017b; García-226 
Villalba et al. 2010), due to the absence of the ortho-diphenolic structure needed for the 227 
COMT enzyme to methylate (Mateos, Goya, and Bravo 2005). Thus, only OH-TY and 228 
deacetoxy-oleuropein-aglycone derivatives undergo methylation. However, TY methylated 229 
conjugates have been identified in one study (Suárez et al. 2011) in plasma samples, 230 
suggesting the presence of enzymatic activity able to methylate tyrosol-like molecules such as 231 
OLC. 232 
Sulfotransferases catalyze the transfer of a sulfate moiety from 3'-phosphoadenosine-233 
5'-phosphosulfate to a hydroxyl group on various substrates (steroids, bile acids, polyphenols, 234 
etc.), and the reaction occurs mainly in the liver rather than in the small intestine (64). These 235 
enzymes could sulfate OLC and OLE, but no sulfate metabolites of OLC have been identified 236 
in any study in humans to date (Silva et al. 2017a; García-Villalba et al. 2010). A possible 237 
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reason for the absence of such metabolites is that OLC inhibits the sulfotransferases by 238 
mimicking the activity of other polyphenols (Gee et al. 1998; Burchell and Coughtrie 1997). 239 
Another plausible explanation is that sulfation is generally a higher-affinity, lower-capacity 240 
pathway than glucuronidation in the same substrate, which if ingested at higher doses results 241 
in a shift from sulfation toward glucuronidation (Koster et al. 1981). In studies this could be 242 
overcome by administering very low doses of the substrate. On the contrary, in a recent study 243 
OH-TY-sulphate-3′ was the major metabolite detected in urine after a high dose 244 
administration of OH-TY to healthy volunteers (Khymenets et al. 2016). OH-TY-sulfate and 245 
OH-TY-acetate-sulfate were the main circulating metabolites detected in both urine and 246 
human plasma (López de las Hazas et al. 2018; Rubió et al. 2014). In a study on human 247 
HepG2 cells, no sulphate conjugates of any of the assayed phenols (OH-TY and TY) were 248 
detected (Mateos, Goya, and Bravo 2005), so human trials are necessary to confirm this 249 
pathway. 250 
Phase 2 metabolites excreted in the bile can be deconjugated by colonic microbiota, 251 
and either degraded to more simple compounds such as phenolic acids (Corona et al. 2006; 252 
Scalbert and Williamson 2000), or reabsorbed as aglycones through intestinal membranes, 253 
completing an enterohepatic recycling (Manach et al. 2004). There is a lack of research on the 254 
specific location of the steps by which polyphenols such as SEC are metabolized, and thus 255 
only tentative metabolic pathways can be given (Fig. 3). 256 
 257 
4. Health effects 258 
SEC, as well as other EVOO polyphenols, have been targeted by numerous studies 259 
aiming to understand the health effects of EVOO consumption. However, OLC and OLE have 260 
not been extensively studied, so their full potential as health-promoting compounds remains 261 
unknown. Most research on OLC and OLE bioactivity has been performed in vitro, whereas 262 
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their effects in the human body might be different, because these molecules may undergo 263 
modifications such as glucuronidation or hydrolyzation during absorption and metabolism 264 
(Silva et al. 2017b). Studies are also limited if experiments are not performed with 265 
physiological concentrations (Espín, García-Conesa, and Tomás-Barberán 2007). As 266 
mentioned before, OLC and OLE absorption and metabolism are still poorly understood, so to 267 
improve the design of future in vitro research, their biotransformation and bioavailability need 268 
further study. In the next sections, the health effects of these polyphenols are discussed, being 269 
broadly shown in Fig. 4 and fully summarized in Tables 1 and 2. 270 
4.1 Oleocanthal 271 
In 2005, Beauchamp and co-workers (Beauchamp et al. 2005) correlated the anti-272 
inflammatory activity of OLC with its inhibitory effect on COX-1 and COX-2, enzymes 273 
responsible for producing inflammatory mediators such as prostaglandins and thromboxane 274 
(Rosignoli et al. 2013). The anti-inflammatory activity of OLC was higher than that of 275 
ibuprofen, the typical drug prescribed for inflammatory processes. Many diseases have been 276 
attributed to chronic inflammatory processes, aggravated by aging, including atherosclerosis, 277 
arthritis, cancer, diabetes and Alzheimer’s disease (AD). The following sections describe the 278 
effect of OLC on inflammatory-mediated diseases and its function in health. 279 
4.1.1. Arthropathy 280 
OLC ameliorates osteoarthritis and rheumatoid arthritis in vitro. Osteoarthritis is 281 
characterized by mechanical stress in the joints, although inflammation contributes to its 282 
symptoms and progression (Bonnet and Walsh 2005). In contrast, rheumatoid arthritis is 283 
caused mainly by inflammation, specifically an auto-immune process. In both cases, pro-284 
inflammatory cytokines and other mediators create an inflammatory state that leads to the up-285 
regulation of cartilage-degrading factors (Goldring and Otero 2011). The down-regulating 286 
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effect of OLC on these cytokines and mediators has been determined (Iacono et al. 2010; 287 
Morena Scotece et al. 2012). 288 
In a study carried out by Iacono and co-workers (Iacono et al. 2010), a chondrogenic 289 
cell line was stimulated with lipopolysaccharide (LPS) to induce the production of nitric 290 
oxide (NO), a mediator in the pathogenesis of osteoarthritis, in the presence and absence of 291 
OLC. The OLC-treated cells produced less NO than the non-treated control, which was 292 
attributed to the phosphorylation of the p38 kinase that promotes the inhibition of the 293 
inducible NO synthase (iNOS), the enzyme responsible for NO production (Iacono et al. 294 
2010). In further experiments the same research group investigated how OLC in chondrogenic 295 
and macrophage cell lines (Morena Scotece et al. 2012), also stimulated with LPS, affected 296 
the production of the pro-inflammatory cytokines, macrophage inflammatory protein 1α 297 
(MIP-1α), interleukin (IL) 6, and NO (Morena Scotece et al. 2012). The results showed that 298 
OLC inhibited the expression and production of these pro-inflammatory cytokines in 299 
chondrogenic cells and decreased their expression and production in macrophages. It was also 300 
able to reduce the iNOS expression and production of NO and pro-inflammatory cytokines, 301 
IL-1β, tumor necrosis factor α (TNF-α) and the granulocyte-macrophage colony-stimulating 302 
factor in these macrophages (Morena Scotece et al. 2012). Further in vivo studies and human 303 
trials are needed to assess all the effects of these SEC on arthropathies.  304 
 305 
4.1.2 Cancer  306 
Cancer is a multifactorial disease characterized by uncontrolled cell proliferation with 307 
the potential to invade or spread to other parts of the body. To control this abnormal cell 308 
growth, anti-cancer drugs are designed to reduce cell proliferation and to promote cell death 309 
(Thurston 2006). Studies have shown that OLC exhibits anti-cancer activity in both processes 310 
using different mechanisms of action (R. Fabiani 2016). 311 
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Cancer proliferation can be controlled by tyrosine-protein kinase Met (c-Met) 312 
phosphorylation. In vitro studies have shown that OLC is able to reduce the expression of the 313 
c-Met receptor, which seems to be involved in tumor growth, survival and angiogenesis (Akl 314 
et al. 2014; Elnagar, Sylvester, and El Sayed 2011). OLC also inhibits the heat shock protein 315 
(Hsp90), which leads to an improper folding of the tumor cell proteins and finally to a 316 
decrease in tumor growth (Margarucci et al. 2013). Another target of OLC is the transcription 317 
factor STAT3, whose downregulation blocks its products, resulting in an inhibition of 318 
hepatocellular carcinoma cell growth and metastasis, both in vitro and in vivo (Pei et al. 2016; 319 
Gu, Wang, and Peng 2017). OLC also has the ability to downregulate the extracellular signal–320 
regulated kinases (ERK1/2) and the protein kinase B (AKT) cell signaling pathways, reducing 321 
the ERK1/2, P90 ribosomal s6 kinase and AKT phosphorylation and inhibiting cell 322 
proliferation in melanoma (Fogli et al. 2016), myeloma (M. Scotece et al. 2013), and non-323 
melanoma skin cancer (Polini et al. 2018), as well as colon and breast cancers (Khanal et al. 324 
2011).  325 
Another mechanism of action that can halt or eradicate cancer is apoptosis. LeGendre 326 
and co-workers (LeGendre, Breslin, and Foster 2015) showed that in the absence of caspase-3 327 
or poly (ADP-ribose) polymerase (PARP), enzymes involved in cell apoptosis, OLC 328 
increased the phosphorylation of ERK1/2 of cancer cells, which rapidly causes cell death 329 
through necrosis. In the same study, OLC showed an ability to selectively change the 330 
lysosomal membrane permeabilization, which helps to liberate pro-apoptotic enzymes in 331 
tumor cells. Furthermore, OLC inhibits the mammalian target of rapamycin (mTOR), which 332 
blocks mitotic cells in the G1 phase and results in apoptotic cell death (Khanfar et al. 2015). 333 
Recent discoveries show that OLC has an antitumor effect through increasing intracellular 334 
reactive oxygen species (ROS) in liver and colon cancer cells, which brings about cell death 335 
(Antonella Cusimano et al. 2017). OLC also induces the activation of apoptosis mechanisms 336 
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such as the cleavage of PARP and caspase-3, which causes DNA fragmentation in tumor cells 337 
(Khanal et al. 2011; M. Scotece et al. 2013; Akl et al. 2014; Gu, Wang, and Peng 2017). 338 
Other apoptosis-promoting effects of OLC are a decrease in the expression of antiapoptotic 339 
protein Bcl2 (Fogli et al. 2016), and the inhibition of COX-2, resulting in the activation of 340 
AMP-activated protein kinase and ultimately apoptosis of the tumor cell (Khanal et al. 2011). 341 
Khanal and co-workers (Khanal et al. 2011) showed that OLC inhibits the activity of 342 
activator protein 1, a transcription factor that controls cell differentiation, proliferation and 343 
apoptosis. OLC inhibits MIP-1α in multiple myeloma cells, which promotes apoptosis and 344 
curtails cell proliferation (M. Scotece et al. 2013). This polyphenol was found to inhibit 345 
migration and invasion in vitro, preventing tube formation in human endothelial cells and thus 346 
impeding metastasis (Gu, Wang, and Peng 2017). 347 
Finally, OLC, which modulates the estrogen receptor (ER) α (Keiler et al. 2015), has 348 
proved to be effective against breast cancer in in vitro assays (Ayoub et al. 2017). The 349 
inhibition of ER-α impedes 17β-estradiol-induced proliferation (Ayoub et al. 2017). In the 350 
same work, Ayoub and co-workers showed that OLC and tamoxifen (an antitumor drug) work 351 
synergically against breast cancer (Ayoub et al. 2017). 352 
 353 
4.1.3 Neurological diseases 354 
The OLC neuroprotective effect has been mainly studied in Alzheimer’s disease (AD), 355 
due to the latter’s prevalence in current society, but it has also been found useful for treating 356 
traumatic brain injury. The major effect of OLC on neurological diseases is linked to a 357 
capacity to reduce oxidative stress and prevent apoptosis in neuronal cells (Mete et al. 2017). 358 
AD is a slow-progressing neurodegenerative disorder characterized by the misfolding, 359 
aggregation and increased toxicity of the β-amyloid peptide and tau protein in the brain. The 360 
misfolded protein and peptide act as a prion inside the brain, causing aggregation and 361 
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inducing neuronal apoptosis and inflammatory signals (Nussbaum, Seward, and Bloom 2013). 362 
OLC reduces AD symptoms by acting on both β-amyloid and tau, and lessening their toxicity. 363 
Firstly, OLC inhibits mTOR, which is involved in the synthesis of β-amyloid and tau 364 
(Khanfar et al. 2015). Secondly, it is able to change the β-amyloid structure, resulting in a 365 
protein that is easier to eliminate, less reactive and less toxic (Qosa et al. 2015; Abuznait et al. 366 
2013; Pitt et al. 2009; Batarseh et al. 2017). Thirdly, OLC can inhibit the fibrillation of the tau 367 
protein, modifying it to a conformationally more stable secondary structure, hence preventing 368 
its abnormal functionality (Monti et al. 2012; Li et al. 2009). OLC induces P-glycoprotein 369 
expression and functionality, which is responsible for β-amyloid clearance (Shinde et al. 370 
2015; Abuznait et al. 2011; Qosa et al. 2015). OLC also protects neurological cells from 371 
apoptosis, reducing ROS levels and upregulating Hsp90 and AKT, two proteins in charge of 372 
cell viability (Giusti et al. 2018). OLC could be used as a complement in AD care, enhancing 373 
the effect of donepezil, a drug for AD treatment that helps to eliminate β-amyloid through the 374 
blood brain (Batarseh and Kaddoumi 2018). 375 
Parkinson’s disease, another neurological disorder highly prevalent in elderly people, 376 
also features an abnormal protein aggregation. OLC could be a candidate drug against this 377 
disease, ameliorating its symptoms as it does with AD (Dauer and Przedborski 2003; 378 
Angeloni et al. 2017). 379 
 380 
4.1.4 Cardiovascular diseases 381 
Olive oil rich in OLC has shown several effects against cardiovascular diseases, such 382 
as improvement in endothelial function in patients with early atherosclerosis (Widmer et al. 383 
2014) and an anti-platelet effect in healthy men (Agrawal et al. 2017). It has also exhibited 384 
nuclear factor κB inhibition (Brunelleschi et al. 2007), which leads to a reduced expression of 385 
17 
 
vascular cell adhesion molecule 1 (VCAM-1), thus decreasing leukocyte adherence in the 386 
endothelium and promoting a normal endothelial function (Libby 2006). 387 
Despite the considerable research accomplished in this field, more data are required to 388 
fully understand the properties and health potential of this olive oil polyphenol. In particular, 389 
studies are needed to determine the effect of OLC on the sirtuin family of proteins, which 390 
regulate genome maintenance, longevity, and metabolism (Milne and Denu 2008), and are 391 
responsible for cellular mechanisms like aging, transcription, apoptosis, and inflammation 392 
(Preyat and Leo 2012). Another potential therapeutic target of OLC is the prevention and 393 
treatment of type 2 diabetes. This disease is characterized by insulin resistance caused by the 394 
non-phosphorylation of the insulin receptor of the cell, which is blocked by pro-inflammatory 395 
molecules such as TNF-α (Wellen and Hotamisligil 2005). Hence, OLC may have the ability 396 
to reduce insulin resistance by the inhibition or reduction of these pro-inflammatory 397 
molecules. A recent study proposed a link between OLC/OLE and diabetes after discovering 398 
that a leaf extract rich in OLC and OLE diminished hyperalgesia in diabetic rats. This 399 
neuropathic disorder produced by damage in the peripheral nervous system is a typical 400 
complication of chronic diabetes (M. E. Czerwińska et al. 2018). 401 
4.2 Oleacein 402 
OLE also displays beneficial properties for human health, with in vitro protective 403 
effects against atherosclerosis and oxidation, and anti-inflammatory activity (Rosignoli et al. 404 
2013; Paiva-Martins and Gordon 2005; Angelino et al. 2011). Its full therapeutic potential 405 
remains to be elucidated, but every year new data point to OLE as the main phenol 406 
responsible for the positive effect of olive oil on cardiovascular disease. To date, it is known 407 
to prevent oxidation, inhibit neutrophil adhesion, and reduce blood pressure (Naruszewicz, 408 
Czerwiska, and Kiss 2015). Other health-promoting activities of OLE in the organism include 409 
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metal ion chelation (Paiva-Martins and Gordon 2005) and anti-inflammatory activity through 410 
COX-2 inhibition (Rosignoli et al. 2013). 411 
The protective effect of OLE against cardiovascular diseases, mainly atherosclerosis, 412 
is due to different actions: reduction of oxidation, demonstrated by in vitro free radical 413 
scavenging (Angelino et al. 2011; Paiva-Martins and Pinto 2008; M. Czerwińska, Kiss, and 414 
Naruszewicz 2012); lowering of hypertension through the inhibition of the angiotensin-415 
converting enzyme (Hansen et al. 1996), and suppressing the in vitro production of 416 
superoxide (Rosignoli et al. 2013; M. Czerwińska, Kiss, and Naruszewicz 2012) and LPS-417 
induced NO (M. Czerwińska, Kiss, and Naruszewicz 2012; Sindona et al. 2012). Also, OLE 418 
decreases inflammation by the inhibition of TNF-α-induced production of the pro-419 
inflammatory gene CCL2 and inhibition of CCL2 transcription (Sindona et al. 2012). 420 
Czerwińska and co-workers (M. Czerwińska, Kiss, and Naruszewicz 2012) discovered 421 
that OLE reduced neutrophil release by myeloperoxidase, which is responsible for lipid 422 
peroxidation and generates reactive nitrogen species (RNS). Thus, OLE reduced the level of 423 
low-density lipoprotein (LDL) in the atherogenic form. In additional experiments, 424 
Czerwińska and co-workers (M. E. Czerwińska, Kiss, and Naruszewicz 2014) found that OLE 425 
induced a decrease in CD11b and CD18 expression and increased CD62L expression, which 426 
prevents neutrophil adhesion and enables them to roll along the vascular wall. OLE also 427 
inhibited neutrophil endopeptidase activity, protecting natriuretic peptides from degradation 428 
and impeding the release of neutrophil elastase. 429 
In addition, OLE exhibited a downregulatory effect on the expression of adhesion 430 
molecules VCAM-1, intercellular adhesion molecule 1 (ICAM-1) and E-selectin (Sindona et 431 
al. 2012). In other in vitro experiments, OLE produced a decrease in the high-mobility group 432 
protein B1, a cell ischemia and cell damage biomarker (Filipek et al. 2017), whose 433 
stimulation increased the expression of ICAM-1 and VCAM-1 on the surface of endothelial 434 
19 
 
cells (Klune et al. 2008). It also reduced tissue factor secretion, which is a potent activator of 435 
the coagulation cascade (Filipek et al. 2017). OLE enhanced anti-inflammatory activity by 436 
stimulating the expression of CD163, an anti-inflammatory gene, increasing the secretion of 437 
two anti-inflammatory factors, IL-10 and heme oxygenase (HO) 1 (Filipek et al. 2015). OLE 438 
also inhibited arachidonate 5-lipoxygenase, which is responsible for the first steps in the 439 
biosynthesis of pro-inflammatory leukotrienes (Vougogiannopoulou et al. 2014). Moreover, it 440 
has recently been found to exert a protective effect in humans against atherosclerosis, and 441 
OLE-rich olive oil had an anti-platelet effect in healthy men (Agrawal et al. 2017). 442 
The endothelial restoring capacity of OLE was tested in endothelial progenitor cells, 443 
which are responsible for neovascularization of ischemic tissue and participate in the re-444 
endothelization of an injured arterial wall. Cells from healthy patients were treated with 445 
angiotensin II and were in contact or not with OLE or oleuropein. When the cells were treated 446 
with the polyphenols, proliferation and telomerase activity increased, and the percentage of 447 
senescent cells and intracellular ROS formation decreased. The polyphenols restored the 448 
migration, adhesion and tube formation of the endothelial progenitor cells reduced by 449 
angiotensin II. The beneficial effect was attributed to an activation of nuclear factor 450 
(erythroid-derived 2)-like 2 and an increase of HO-1 expression, OLE being more efficient 451 
than oleuropein (Parzonko et al. 2013). 452 
 In vitro studies demonstrated that OLE has a protective role in human blood cells 453 
against oxidative-induced hemolysis (Paiva-Martins et al. 2010). It reduced H2O2-induced 454 
DNA damage in human blood mononuclear cells (R Fabiani et al. 2008) and also protected 455 
LDL from oxidation (Visioli et al. 1995). OLE showed an anti-cancer effect, promoting 456 
apoptosis in leukemia cells (Roberto Fabiani et al. 2006) and in non-melanoma skin cancer 457 
cells (Polini et al. 2018). Finally, OLE had an antiestrogenic effect, binding both ER-α and 458 
ER-β (Keiler et al. 2015). 459 
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In summary, OLE provided protection against atherosclerosis by reducing 460 
hypertension (Hansen et al. 1996), preventing neutrophil adhesion, reducing oxidative 461 
damage (M. E. Czerwińska, Kiss, and Naruszewicz 2014), improving injured cell wall 462 
recovery (Parzonko et al. 2013), promoting anti-inflammatory chemokines (Filipek et al. 463 
2015), and inhibiting pro-inflammatory chemokines (Sindona et al. 2012). OLE  has also 464 





5. Conclusion  468 
In the last 15 years, the secoiridoids OLC and OLE have been a focus of research on 469 
EVOO. Their biosynthesis and biotransformation during the growth of the olive crop and in 470 
the oil extraction process have been studied with the aim of increasing their final 471 
concentration in EVOO. Further experiments are required to assess the stability of these 472 
compounds in the oil. 473 
The mechanisms of OLC and OLE absorption are unclear, but possibly include passive 474 
diffusion. In human studies, the OLC metabolites found in plasma and urine have been mainly 475 
attributed to processes of hydrogenation, hydration, hydroxylation and glucuronidation. 476 
However, more research is required on the extent of absorption and metabolism processes, 477 
which will shed light on the bioavailability of these SEC and their plasma concentration 478 
levels. 479 
The protective effects of OLC and OLE have been widely investigated in vitro and 480 
some studies have been conducted in vivo. OLC shows therapeutic promise against cancer, 481 
arthropathy, AD and cardiovascular diseases, but its full health-promoting capacity remains 482 
undetermined. More studies, in vitro with cells and tissues and in vivo with animals, and 483 
clinical trials are required to draw better conclusions. Like OLC, OLE is still under-explored 484 
by the scientific community, but results to date show protective effects against atherosclerosis 485 
and cancer. Finally, additional efforts are needed to discover and characterize new properties 486 
of these compounds. 487 
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Table 1. Health effects of OLC 1 
    Ref Cell model 
OLC concentration/ 
treatment 
Mechanism of action Biological effect 
Inflammation 





COX-1, COX-2, LOX 
inhibition assay kit 
7, 25, 100 µM. 







Human monocytes stimulated 
with Lps 









HeLa and Caco-2 10 µM Inhibition of mTOR 
Inhibition of mTOR arrests apoptosis-causing mitotic cells 









MDA-MB-231 5-20 µM IC50= 15 µM 
Inhibition of C-met 
phosphorylation 




MDA-MB-231, MCF-7 and 
BT-474 MDA-MB-231 in 
athymic nude mice  
5-15 µM (Significant 
effect from 5 µM) 
Inhibition of C-met 
phosphorylation 
Reduction of ERK1/2 and 
AKT phosphorylation 
Cleavage of PARP and 
caspase-3 
Decrease of tumor growth, survival and angiogenesis 








MDA-MB-231 20 µM 
During serum starvation 
condition, activation of 
ERK1/2 phosphorylation 
without cleavage of 
caspase-3 or PARP 
Inhibition of acid 
sphingomyelinase 
Cell necrosis 
Change in lysosomal membrane permeabilization, and 










10 µM Inhibition of Mtor 
Inhibition of mTOR arrests apoptosis-causing mitotic cells 
in the G1 phase 
(Ayou
b et al. 
2017) 
BT-474, MCF-7, T-47D   
BT-474 in mice 
1-80 µM (Significant 
effect from 20 µM) 






HCT-116 and HT-29  
JB6 Cl41 murine 
1-10 µg·mL-1 
(Significant effect from 
1 µg·mL-1) 
Reduction of ERK1/2 and 
p90RSK phosphorylation 
Inhibition of ap-1 activity 
Activation of AMPK 
Inhibition of COX-2 
Cleavage of PARP and 
caspase-3. 
Reduction of cancer proliferation 






SW480, HT29 50 µM 
Increase of ROS 
concentration 






Huh-7, HepG2 and HCCLM3 
Male BALB/c athymic nude 
mice 




Blocking of STAT 3 
activation 






HepG2, Hep3B, Huh7, 
PLC/PRF/5 
50 µM  
Increase of ROS 
concentration 





i et al. 
2006) 
HL60 7.5-120 µM  
Less proliferation  





e et al. 
2013) 
ARH-77 (human) and MOPC-
31C (murine)  
10-50 µM IC50= 10 µM 
Reduction of ERK1/2, 
p90RSK and AKT 
phosphorylation  
Inhibition of MIP-1α 
Cleavage of PARP and 
caspase-3 
Reduction of cancer proliferation 
 
Activation of apoptosis 










BxPC3 20 µM 
During serum starvation 
condition, activation of 
ERK1/2 phosphorylation 
without cleavage of 
caspase-3 or PARP 
Inhibition of acid 
sphingomyelinase 
Cell necrosis  
Change in lysosomal membrane permeabilization and 









PC3 5-20 µM IC50=20µM 
Inhibition of Cmet 
phosphorylation 







PC3 20 µM 
During serum starvation 
condition, activation of 
ERK1/2 phosphorylation 
without cleavage of 
caspase-3 or PARP 
Inhibition of acid 
sphingomyelinase 
Cell necrosis  
Change in lysosomal membrane permeabilization and 





A375 and 501Mel 
10 µM  
IC50 (A375)= 13.6 µM, 
IC50 (501Mel)=20 µM 
Reduction of ERK1/2, 
p90RSK and AKT 
phosphorylation 
Decrease expression of 
Bc12 
Reduction of cancer proliferation 






A375 or A2058  
 
HUVEC 
20-40 µM (Significant 
effect from 20 µM) 
Caspase-3, caspase-9 and 
PARP cleavage 
Inhibition of tube 
formation 
Induction of apoptosis 




A431 (non-melanoma skin 
cancer) 
1-100, IC50= 30 µM 
Less phosphorylation of 
Akt and ERK1/2 








o et al. 
2010)  
ATDC5 
1-25 µm (Significant 
effect from 5 µM) 
Reduction of LPS-induced 
NO 
Phosphorylation of p38 
kinase 






e et al. 
2012) 
ATDC5 and J774 50 µM 
Inhibition of MIP-1α and 
IL-6 
Reduction of NO 
production and iNOS 
Reduction of IL-1β, TNF-α 
and GM-CSF 





Human monocytes 100 µM 
Reduction of LPS-induced 
NO 
Less joint inflammation 
Alzheimer’s disease 





0-100 µM (Significant 
effect from 0.01 µM) 
Change in oligomeric 
structure of Aβ 
Reduction of Aβ binding 
Increased immunoreactivity and less deterioration of 
dendritic spines. 






0.5-50 µM (Significant 
effect from 0.5 (P-gp) 
and 1 µM (LRP1)) 
Induction of P-gp and 
LRP1 









TgSwDI mice  
hCMEC/D3, SH-SY5Y-APP  
5 mg.kg·day-1 OLC for 
4 weeks.  
0,1,5,10 µM 
(Significant effect from 
5 µM)  
Up-regulation of P-gp, 
LRP1 and ApoE-dependent 
pathway 
Reduction of astrocyte 
activation and IL-1β 
Increase in P-gp and LRP1 
expression 
Reduction of brain inflammation caused by AD 





CCF-STTG1 and SH-SY5Y 5 µM  
Reduction of IL-6 and 
GFAP levels after 7 days  
Reduction of the 
expression of GLT1 and 
PSD-95 
Less AD-associated inflammation 
Reduction of Aβo-induced down-regulation of synaptic 
protein  
(Giust
i et al. 
2018) 
SH-SY5Y 
1-10 µM (Significant 
effect from 1 µM) 
Less ROS, upregulation of 
Hsp90 and Akt 
Inhibition of apoptosis 














1-100 µM (Significant 
effect from 1 µM) 
Inhibition of tau 
transformation from 
random coil to β-sheet 
Tau more stable 
(Mont
i et al. 
2012) 
Chemical assay 60-100 µM 
Schiff base between 
aldehyde and NH2 of lys 
residue of tau 
Tau more stable 
CVD 







Olive oil extract rich in 
OLC (1.855 g·L-1) 






trial with 82 patients with 
early atherosclerosis 
30 mL·day-1 of EVOO 
rich in OLC (70 mg·L-
1) 
Reduction in ICAM, WBC, 
lymphocytes, monocytes 
and platelet count 






controlled crossover study, 
with 27 healthy men 
40 mL of EVOO rich in 
OLC (310 mg·L-1) 
Anti-platelet Protection against atherosclerosis 
Abbreviations: COX-1: Cyclooxygenase 1, COX-2: Cyclooxygenase 2, LOX: Lipoxygenase, Lps: lipopolysaccharide, mTOR: mammalian target of rapamycin, c-Met: 2 
tyrosine-protein kinase Met, ERK1/2: extracellular signal–regulated kinases, AKT: protein kinase B, PARP: Poly (ADP-ribose) polymerase, P90RSK: P90 ribosomal s6 3 
kinase, Ap-1: Activator protein 1, AMPK: AMP-activated protein kinase, ROS: Reactive oxygen species, STAT3: Signal transducer and activator of transcription 3, MIP-1α: 4 
Macrophage Inflammatory Protein 1α, Bcl2: B-cell lymphoma 2, IL-6: Interleukin 6, iNOS inducible nitric oxide synthase, Il-1β: Interleukin 1β, TNF-α: Tumor necrosis 5 
factor α, GM-CFS: Granulocyte-macrophage colony-stimulating factor, Aβ: Amyloid-β, P-gp: P-glycoprotein, LRP1: Low density lipoprotein receptor-related protein 1, 6 
ApoE: Apolipoprotein E, IL-1β: Interleukin 1β, GFAP: Glial fibrillary acidic protein, GLT1: glutamate transporter 1, PSD-95: Post synaptic density protein 95, Hsp90: heat 7 
shock protein 90, Nf-κB: Nuclear factor κB, ICAM-1: Intercellular Adhesion Molecule 1, VCAM-1: Vascular cell adhesion molecule 1, WBC: White blood cells.8 
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Table 2: Health effects of OLE. 9 
  Ref Cell model 
OLE concentration/ 
treatment 





(Visioli et al. 1995) Healthy human LDL 10 µM 




(Hansen et al. 1996) 
Angiotensin converting enzyme 
from rabbit lung 
IC50 = 26 µM Ace inhibition Hypertension 
(Paiva-Martins and 
Gordon 2005) 
Buffer solutions 3.5, 5.5, 7 400 µM Fe chelator Metal chelator 
(Paiva-Martins and Pinto 
2008) 
Water/methanol solution 
IC50= 0.3mol OLC/mol 
radical compound 
Radical scavenging 
Reduction of cell oxidative 
damage 
(M. Czerwińska, Kiss, and 
Naruszewicz 2012) 
Chemical assay 
1-50 µM (Significant effect 
from 10 µM) 
Radical scavenging 
Reduction of cell oxidative 
damage 
(Vougogiannopoulou et al. 
2014) 
Isolated human recombinant 5-
LO 
IC50= 2 μM 5-LO inhibition 
No formation of pro-
inflammatory leukotrienes 
White blood  
cell 
(R Fabiani et al. 2008) Human blood mononuclear cells 10 µM 
Reduction of H2O2-
induced DNA damage 
DNA protection 
(M. Czerwińska, Kiss, and 
Naruszewicz 2012) 
Human neutrophils 10 µM 
Reduction of Lps-induced 
NO-production 
Reduced inflammation 
Reduction of lipid 
peroxidation release 
Reduction of RNS 
Reduction of atherogenic form 
of LDL 
(Rosignoli et al. 2013) Human monocytes 100 µM 
Cox-2 inhibition  
Reduction of superoxide 
production 
Antiinflammatory  
Reduction of cell oxidative 
damage 
(M. E. Czerwińska, Kiss, 
and Naruszewicz 2014) 
Human isolated neutrophils 
20,50,100 µM (Significant 
effect from 20 µM) 
Less CD11b and CD18 
expression, more CD62L 
expression 
Inhibition of neutrophil 
elastase, MMP-9 and IL-8 
release 
Inhibition of neutrophil 
endopeptidase activity 
Less neutrophil adhesion and 
easier to roll along the 
vascular wall 
Less inflammation 
Protection of natriuretic 
peptides from degradation 
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(Filipek et al. 2015) Monocyte/macrophage cells 
10-20 µM and Hemoglobin-
haptoglobin complex 
(Significant effect from 10 
µM) 
Stimulation of CD163 gene 
expression 
Increase in secretion of IL-
10 and HO-1 
Reduced inflammation 
Other blood  
cells 
(Paiva-Martins et al. 2010) Human red blood cells 
5-10 µM (Significant effect 
from 5 µM) 
Interaction between 
oleacein and RBC 
membrane proteins 
Protection of RBCs from 
oxidative-induced hemolysis 
(Angelino et al. 2011) Human red blood cells 0.7 mg·g-1 Radical scavenging 
Reduction of cell oxidative 
damage 
(Sindona et al. 2012) 
HUVEC human umbilical vein 
endothelial cells 
10 µg·mL-1 
Reduction of lps-induced 
no-production  
Inhibition of TNF-α 
induced CCL2 
transcription 
Less VCAM-1 and ICAM-
1 expression 
Less e-selectin expression 
Less inflammation 
Less neutrophil adhesion 
(Parzonko et al. 2013) 
Human endothelial progenitor 
cells 
1-10 µM (Significant effect 
from 1 µM) 
Activation of nrf2 
Increase of HO-1 
Restored migration, adhesion 
and tube formation of 
endothelial progenitor cells 
(Filipek et al. 2017) Human isolated carotid plaques 
5-20 µM (Significant effect 
from 5 µM) 
Decreased HMG1  
Less TF secretion  
Less cell damage 
Less adhesion of neutrophils 




(Widmer et al. 2014) 
Double-blind, randomized trial 
with 82 patients with early 
atherosclerosis 
30 mL·day-1 of EVOO rich 
in OLE (73 mg·L-1) 
Reduction in ICAM, WBC, 
lymphocytes, monocytes 
and platelet count 
Improvement of endothelial 
function 
(Agrawal et al. 2017) 
Double-blind, randomized 
controlled crossover study with 
27 healthy men 
40 mL of EVOO rich in 











effect from 17.5 µM) 
  
Less proliferation 
Increase of apoptosis 
(Polini et al. 2018) A431(non-elanoma skin cancer) 1–100 μM, IC50= 10 µM  
Less phosphorylation of 
Akt and ERK1/2 




(Keiler et al. 2015) MVLN cells 
10 nM-10 µM (Significant 
effect from 10 µM) 
Binds ER-α and ER-β Antiestrogenic effect 
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Abbreviations: LDL: Low density lipoprotein, ACE: Angiotensin-converting enzyme, 5-LO: Arachidonate 5-lipoxygenase, Lps: lipopolysaccharide, COX-2 Cyclooxygenase 10 
2, RNS: Reactive nitrogen species, MMP-9: Matrix metallopeptidase 9, IL-8: Interleukin 8, IL-10: Interleukin 10, HO-1: Heme oxygenase 1, RBC: Red blood cells, TNF-α: 11 
Tumor necrosis factor α, CCL2: C-C Motif Chemokine Ligand 2, ICAM-1: Intercellular Adhesion Molecule 1, VCAM-1: Vascular cell adhesion molecule 1, Nrf2: Nuclear 12 
factor (erythroid-derived 2)-like 2, HMG1: high-mobility group protein 1, TF: tissue factor, WBC: White blood cells, AKT: protein kinase B,  ERK1/2: extracellular signal–13 
regulated kinases, ER-α: Estrogen receptor α, ER-β Estrogen receptor β. 14 
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Figure Captions 15 
Figure 1 Biosynthesis of secoiridoids in Olea europaea L 16 
Figure 2. First gastrointestinal steps encountered by the OLC molecule after oral administration. According to 17 
several studies, the ester bond is partially affected, but the intact molecule of OLC will ultimately reach the 18 
blood stream. 19 
Figure 3. Plausible metabolic pathways OLC according to the literature.  20 
ALK (stands for NADPH-dependent aldoketoreductase, produces hydrogenation), CYP450 (produces 21 
hydroxylation, and oxidation changes), UGT (stands for UDP-glucuronosyl transferase), COMT (stands for 22 
cathecol-O-methyl-transferase, and has apparent specificity for ortho-diphenolic structures, but according to 23 
Rubió et al 2012. tyrosol-like structures could suffer methylation), SULT (stands for sulfotransferase), difficult 24 
to identify one enzyme responsible for hydration. 25 
Figure 4: Benefficial effect of oleocanthal in AD  26 
 27 
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